Results 331 to 340 of about 1,311,555 (408)

Neurovascular coupling in bone regeneration: Mechanisms, advanced biomaterials and challenges

BMEMat, EarlyView.
This figure illustrates various material strategies for neurovascularized bone regeneration, including electroactive scaffolds, ion‐loaded materials, drug delivery systems, surface modifications, cells/cell products, growth factors, and peptides. These approaches aim to synergistically promote the regeneration of neural, vascular, and bone tissues ...
Yixin Ma, Nan Jiang, Liyuan Chen, He Zhang, Xinjia Cai, Karan Gulati, Danqing He, Zhigang Cai, Yan Liu   +8 more
wiley   +1 more source

International Survey for Antiemetics in Hematopoietic Stem Cell Transplantation in the APBMT Centers. [PDF]

Blood Cell Ther
Yakushijin K, Perram J, Ho A, Farzana T, Iida H, Lee JW, Inamoto Y, George B, Wu D, Suzuki R, Behfar M, Huang H, Asawapanumas T, Rowlings P, Poudyal BS, Santosa D, Gyi AA, Altangerel O, Wanitpongpun C, Gan GG, Iyama S, Iqbal S, Ramzi M, Khadwal A, Kato J, Sim J, Cheng J, Ma D, Chua YX, Okamoto S, Iida M, Fuji S.   +31 more
europepmc   +1 more source

The ageing holobiont: crosstalk between telomere dynamics, oxidative stress and the gut microbiome

Biological Reviews, EarlyView.
ABSTRACT The gut tissue is at the frontline of early onset of ageing. It exhibits high cell turnover rates and rapid telomere shortening, which can have systemic effects on the developing or senescing organism. We conducted a literature review of studies on the crosstalk between telomere length dynamics, telomerase activity, oxidative stress, and gut ...
Michael L. Pepke, Søren B. Hansen, Morten T. Limborg   +2 more
wiley   +1 more source

Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. [PDF]

Blood Adv
Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR.   +19 more
europepmc   +1 more source

Hematopoietic Stem Cells Require Elevated Protein Quality Control [PDF]

, 2018
Dillingham, Christopher, Hatters, Danny, Hong, Yuning, Kruta, Miriama, San Jose, Lorena Hidalgo, Signer, Robert, Sunshine, Mary Jean   +6 more
core  

Isolated Corticospinal Tract Lesions as an Early Manifestation of Adrenoleukodystrophy in Children

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Purpose X‐linked adrenoleukodystrophy (ALD) encompasses a wide range of neurological manifestations, classically described as distinct phenotypes including childhood cerebral adrenoleukodystrophy and adult‐onset adrenomyeloneuropathy (AMN).
Elle Winter, Amanda Nagy, Yedda Li, Otto Rapalino, Catherine L. Becker, Joseph Locascio, Camilo Jaimes, Florian Eichler   +7 more
wiley   +1 more source

Advances in immunotherapy for cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. [PDF]

Immunotherapy
Wang Y, Wu J, Huang X, Xiao Y.
europepmc   +1 more source

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation

Clinical Pharmacology &Therapeutics, EarlyView.
The novel application of Virtual Twins (VT) in PBPK (VT‐PBPK) presents the opportunity to advance precision dosing and accelerate the shift from one‐size‐fits‐all to targeted, individualized treatments. This review aims to: (1) critically evaluate existing research on the use of VTs in PBPK, (2) develop a conceptual definition of VT‐PBPK, (3) describe ...
Emily Mannix, Sam Mostafa, Amin Rostami‐Hodjegan, Thomas M. Polasek, Carl M. J. Kirkpatrick   +4 more
wiley   +1 more source

Long enduring response on teclistamab in a patient with myeloma relapse after allogeneic hematopoietic stem cell transplantation - a case report. [PDF]

Ann Hematol
Ebner P, Fauser J, Hetzenauer G, Köck S, Willenbacher W, Rossetti LM, Buchwald TA, Rasche L, Gunsilius E, Nachbaur D, Wolf D, Steiner N.   +11 more
europepmc   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source